UROTHELIAL CARCINOMA BLADDER
Clinical trials for UROTHELIAL CARCINOMA BLADDER explained in plain language.
Never miss a new study
Get alerted when new UROTHELIAL CARCINOMA BLADDER trials appear
Sign up with your email to follow new studies for UROTHELIAL CARCINOMA BLADDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a nitric oxide blocker make immunotherapy work better?
Disease control CompletedThis early-phase trial tested whether adding L-NMMA to the immunotherapy drug pembrolizumab is safe for people with several types of advanced cancer. The idea is that L-NMMA may remove a brake on the immune system, helping pembrolizumab work better. Only 12 adults took part, and …
Matched conditions: UROTHELIAL CARCINOMA BLADDER
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 17, 2026 09:08 UTC
-
New bladder cancer drug shows promise in early trial
Disease control CompletedThis early-stage study tested a new drug called UGN-301 (zalifrelimab) in 51 people with recurrent non-muscle invasive bladder cancer. The drug was given directly into the bladder to see if it is safe and to find the best dose. The goal is to control the cancer and prevent it fro…
Matched conditions: UROTHELIAL CARCINOMA BLADDER
Phase: PHASE1 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New combo shows promise against three tough cancers
Disease control CompletedThis study tested a new drug combination (IO102-IO103 plus pembrolizumab) as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. A total of 63 patients took part. The goal was to see if the combo could shrink tumors and delay cancer grow…
Matched conditions: UROTHELIAL CARCINOMA BLADDER
Phase: PHASE2 • Sponsor: IO Biotech • Aim: Disease control
Last updated May 14, 2026 12:03 UTC